Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47 Antibody
Status:
Recruiting
Trial end date:
2023-01-27
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, single arm, Phase 1，dose escalation and dose expansion
study designed to evaluate the safety, tolerability, pharmacodynamics, PK, immunogenicity,
and preliminary antitumor activity of AK117 administered intravenously to adult subjects with
relapsed/refractory advanced or metastatic solid tumors or lymphomas.